• Bacillus Strain and Medium Shape γ-Glu-Cys Peptide Productio

  2026-06-08

  This study systematically investigates how Bacillus species and growth media impact the synthesis of γ-glutamyl dipeptides, including the key glutathione metabolism intermediate gamma-Glu-Cys (γ-Glu-Cys). The findings provide researchers with practical insights for optimizing peptide yields in microbial fermentation and food science applications.

• Dabigatran (Pradaxa): Mechanistic Insights and Metabolite Im

  2026-06-08

  Explore the molecular mechanisms and metabolite dynamics of Dabigatran (Pradaxa) in advanced coagulation assays. This in-depth analysis reveals unique insights for researchers optimizing thrombin inhibition and anticoagulant assay design.

• Merbromin as a Selective Mixed-Type Inhibitor of SARS-CoV-2

  2026-06-07

  This study identifies merbromin as a potent and selective inhibitor of the SARS-CoV-2 main protease, 3CLpro, through high-throughput screening and kinetic analysis. The findings provide a new scaffold for antiviral drug development and highlight the specificity of merbromin’s inhibitory action compared to related proteases.

• Trifluoperazine 2HCl: Dopamine D2 Inhibitor Protocols & Inno

  2026-06-06

  Trifluoperazine 2HCl is redefining both neuropharmacology and host-pathogen interaction assays by enabling precise dopamine D2 receptor inhibition and robust host-directed antibacterial workflows. Discover how to maximize its performance, troubleshoot common issues, and leverage the latest mechanistic insights for your next neuroscience or immunology breakthrough.

• Bleomycin Sulfate (A8331): Protocols for DNA Damage & Fibros

  2026-06-05

  Bleomycin Sulfate offers a reliable solution for modeling chemotherapy-induced DNA damage and pulmonary fibrosis in both cellular and animal systems. This reagent is optimal where precise, reproducible induction of DNA strand breaks or fibrotic injury is needed, but is not appropriate for studies requiring ethanol solubility or long-term solution stability.

• Lactate-Driven H3K18la Axis in HCC Immunotherapy Resistance

  2026-06-05

  This study uncovers a pharmaceutically reversible metabolic-epigenetic pathway—lactate-induced histone H3K18 lactylation—that drives immune resistance in hepatocellular carcinoma (HCC) via the KIF20A–c-Myc–PD-L1 axis. Targeting glycolysis disrupts this pathway, restoring anti-tumor immunity and sensitizing HCC to PD-1 blockade, offering new translational strategies for overcoming immunotherapy resistance.

• Caveolin-1 Modulates Cholesterol Homeostasis in MASLD Progre

  2026-06-04

  This study elucidates how Caveolin-1 protects against the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) by restoring cholesterol balance, thereby reducing ER stress and pyroptosis. The findings highlight the mechanistic link between cholesterol accumulation, cellular stress pathways, and liver disease severity, offering new molecular insight for targeted interventions.

• CCR7–Notch1 Crosstalk Maintains Stemness in Mammary Cancer C

  2026-06-04

  Boyle et al. (2017) reveal direct signaling interplay between the CCR7 chemokine receptor and Notch1 pathway that sustains stem-like characteristics in MMTV-PyMT mammary cancer cells. This mechanistic insight highlights the importance of dual-pathway targeting to disrupt cancer stem cell-driven recurrence in breast cancer.

• Resveratrol Disrupts CAF-Driven Breast Cancer Organoid Growt

  2026-06-03

  This study demonstrates that resveratrol inhibits breast cancer organoid proliferation even in the presence of cancer-associated fibroblasts (CAFs), which are known to promote drug resistance. By integrating a patient-derived organoid-CAF co-culture model and quantifying cell proliferation using EdU assays, the research clarifies the mechanism by which resveratrol suppresses tumor-supportive versican (VCAN) expression in CAFs.

• SHC-1 Inhibition Modulates CFTR Surface Abundance in Epithel

  2026-06-03

  This study delineates conserved and cell-type-specific mechanisms by which SHC-1 inhibition increases plasma membrane abundance of the CFTR chloride channel in epithelial cell models. The findings clarify regulatory pathways underlying CFTR trafficking with implications for cystic fibrosis and secretory disease research.

• Luminescent ATP Cell Viability Assay Kit I in Ferroptosis Wo

  2026-06-02

  The Luminescent ATP Cell Viability Assay Kit I empowers researchers to dissect regulated cell death, especially ferroptosis, with unmatched sensitivity and workflow speed. Its robust luciferase luminescence detection accelerates drug screening and mechanistic studies, outperforming traditional viability assays.

• Puromycin Aminonucleoside: Transforming Podocyte Injury Mode

  2026-06-02

  This article explores the mechanistic foundations and translational impact of puromycin aminonucleoside as a gold-standard tool for modeling podocyte injury and nephrotic syndrome. We examine its role in glomerular lesion induction, workflow optimization, and benchmarking in FSGS research, while providing actionable guidance for translational researchers aiming to bridge preclinical insights with clinical relevance.

• U 46619: Precision Platelet Aggregation & Vascular Research

  2026-06-01

  U 46619 (11,9 epoxymethano-prostaglandin H2) is a gold-standard TP receptor agonist that enables high-fidelity modeling of platelet function, vascular tone, and renal responses in experimental settings. Its reproducible potency and robust solubility empower workflows from mechanistic in vitro assays to in vivo hypertension studies.

• Nigericin Sodium Salt: Technical Guidance for Ion Transport

  2026-06-01

  Nigericin sodium salt is a potassium ionophore used to modulate ion gradients and cytoplasmic pH in in vitro research workflows, including studies on ion transport across biological membranes and platelet aggregation modulation. It is not intended for diagnostic or clinical applications and requires careful attention to solubility and handling for reliable results.

• ALT Cancer Cell Sensitivity to ATR Inhibition: Evidence Revi

  2026-05-31

  This article examines the findings of Deeg et al., who rigorously tested whether cancer cells utilizing alternative lengthening of telomeres (ALT) are broadly hypersensitive to ATR inhibition. Contrary to previous expectations, their results demonstrate that ALT status alone does not confer general hypersensitivity to ATR inhibitors, guiding researchers toward more nuanced interpretations of cell viability in cancer models.

470 records 10/32 page Previous Next First page 上5页 678910 下5页 Last page